Salivary Mitofusin-1 Levels in Periodontitis: Associations With Disease Severity, Smoking, and Treatment Response

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorÖmer Faruk Okumuş

About this trial

Periodontitis (gum inflammation) is a common disease worldwide. This study aims to investigate a novel biomarker, a protein called Mitofusin-1 (Mfn1), in saliva that may be associated with the severity of periodontitis and response to treatment. The study will include periodontally healthy individuals, individuals with mild to severe periodontitis, and smokers with severe periodontitis. Participants will receive saliva samples and undergo clinical periodontal examinations. Individuals with periodontitis will receive standard periodontal treatment, and changes in Mfn1 levels will be assessed 3 months after treatment. The study is expected to shed light on the potential utility of Mfn1 as a marker in the diagnosis and follow-up of periodontitis.

Eligibility criteria

Qualifiers

Willing and able to provide written informed consent.

Systemically healthy (no history of diabetes mellitus, immunodeficiency, malignancy, or other systemic conditions that could affect periodontal status).

Have a minimum of 20 natural teeth (excluding third molars).

No antibiotic therapy or periodontal treatment in the last 6 months.

Disqualifiers

Fewer than 20 natural teeth (excluding third molars).

Presence of any systemic disease (e.g., diabetes mellitus, immunological disorders, cancer).

Use of antibiotics or receiving periodontal treatment in the last 6 months.

Pregnancy or lactation.

Trial design

Treatments tested in this trial

  • Non-surgical Periodontal Therapy (Scaling and Root Planing)
  • Saliva Collection

Treatment groups

104 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Ömer Faruk Okumuş

Lead sponsor

Erzincan University

Sponsor institution